News Medical on MSN3h
GLP-1, SGLT2 Drugs Cut Heart Risk for Stroke SurvivorsIn an analysis of more than 7,000 stroke survivors, those who were taking either a GLP1-receptor agonist or an SGLT2 ...
Poor bowel preparation also led to repeat colonoscopies for 18.9% of current GLP-1RA users, compared to 11.1% of controls ...
Medpage Today on MSN6d
Do GLP-1 Agonists Really Need to Be Stopped Before Endoscopy?But patients taking GLP-1 drugs did have a greater likelihood of retained gastric contents and of aborted upper endoscopies, ...
Recent studies have shown that pharmacological treatment with GLP-1-RA and dual GLP-1/glucose-dependent insulinotropic ...
New research presented at the ACG Annual Meeting suggests that GLP-1RAs lower the risk of pancreatic cancer in patients with ...
The use of glucagon-like peptide 1 (GLP-1) receptor agonists in adults with type 2 diabetes mellitus (T2DM) was not ...
Demand for weight loss drugs targeting GLP-1 has exploded in recent years, leading to disruptions in supply chains. Here are ...
Recently the U.S. Food and Drug Administration (FDA) issued updated safety warnings for all glucagon-like peptide 1 receptor ...
Poorer folks' access to blockbuster weight-loss drugs through Medicaid remains ... treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) medications, researchers discovered.
the drugs mimic an incretin hormone, glucagon-like peptide-1, that does exactly that. But, instead, studies have since found that they work in the brain. In fact, the molecular receptors for ...
Novo Nordisk has signed off on a $285 million biobucks deal with fellow Denmark-based company Ascendis Pharma to help the Wegovy manufacturer develop a once-monthly GLP-1 receptor agonist.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback